Search

Your search keyword '"serum thymus and activation-regulated chemokine"' showing total 2 results
Start Over Descriptor "serum thymus and activation-regulated chemokine" Topic severity of illness index
2 results on '"serum thymus and activation-regulated chemokine"'

1. Utility of serum thymus and activation-regulated chemokine as a biomarker for monitoring of atopic dermatitis severity.

Author

Landheer J, de Bruin-Weller M, Boonacker C, Hijnen D, Bruijnzeel-Koomen C, and Röckmann H

Subjects
Adult, Biomarkers blood, Body Surface Area, Female, Follow-Up Studies, Humans, Male, Middle Aged, Retrospective Studies, Young Adult, Chemokine CCL17 blood, Dermatitis, Atopic blood, Severity of Illness Index
Abstract

Background: Serum thymus and activation-regulated chemokine (sTARC) levels reflect disease severity of atopic dermatitis (AD) in small study populations. It remains unclear whether sTARC is a reliable outcome measurement for AD severity in heterogeneous AD populations in daily practice., Objective: We sought to assess the utility of sTARC as a biomarker for monitoring AD severity in adults in daily practice., Methods: sTARC, clinical skin score (Six Area, Six Sign AD [SASSAD]), and body surface area measurements were collected from all adult patients with AD visiting our clinic between March 2009 and March 2012, at first visit or exacerbation (baseline). In addition, data from short-term and long-term follow-up visits were collected., Results: At baseline sTARC levels ranged widely (n = 320; minimum-maximum: 3-50,400 pg/mL) and sTARC and SASSAD or body surface area correlated moderately. In the majority of patients, sTARC and SASSAD or body surface area changed congruently during follow-up., Limitations: Data were collected retrospectively., Conclusion: sTARC may represent a suitable biomarker for monitoring of AD severity in daily practice., (Copyright © 2014 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)

Published
2014
Full Text
View/download PDF

2. Alteration of serum thymus and activation-regulated chemokine level during biologic therapy for psoriasis: Possibility as a marker reflecting favorable response to anti-interleukin-17A agents

Author

Akemi Ishida-Yamamoto, Takashi Shibuya, Masaru Honma, Hidetoshi Takahashi, Shin Iinuma, and Takeshi Iwasaki

Subjects
Male, 0301 basic medicine, Chemokine, Necrosis, Severity of Illness Index, 030207 dermatology & venereal diseases, FAVORABLE RESPONSE, 0302 clinical medicine, Japan, Medicine, Skin, Aged, 80 and over, education.field_of_study, biology, Interleukin-17, Antibodies, Monoclonal, General Medicine, psoriasis, Middle Aged, Biomarker (medicine), biomarker, Female, Interleukin 17, medicine.symptom, Immunosuppressive Agents, Adult, serum thymus and activation-regulated chemokine, Adolescent, Population, Dermatology, Antibodies, Monoclonal, Humanized, Young Adult, 03 medical and health sciences, Psoriasis, Humans, biologic therapy, education, Aged, Biological Products, Tumor Necrosis Factor-alpha, business.industry, Immunoglobulin E, medicine.disease, immunoglobulin E levels, 030104 developmental biology, Immunology, biology.protein, Secukinumab, Chemokine CCL17, business, Biomarkers
Abstract

Biologics show great efficacy in treating psoriasis, a chronic inflammatory skin disease. The high cost and side-effects of biologics, dose-reduction, elongation of administration interval and suspension are possible options. However, there has been no reliable biomarker we can use when we consider these moderations in therapy. This study was conducted to test the possibility of using serum thymus and activation-regulated chemokine (TARC) level as an indicator for step down of biologic therapy. Serum TARC level was measured in 70 psoriatic patients at Asahikawa Medical University, and a correlation of TARC and severity of skin lesions was analyzed. Referring to serum TARC level, psoriatic patients can be divided into two groups. One is a population in which serum TARC level is positively correlated with severity of skin lesions, and the other is a population with low psoriatic severity and high TARC level. Serum TARC level was higher in the group that achieved PASI-clear with biologics than in the group which did not achieve PASI-clear. Among biologics, the group treated with secukinumab, an anti-interleukin (IL)-17A agent, showed significantly higher TARC level compared with the group treated with anti-tumor necrosis factor agents. In certain populations achieving PASI-clear, serum TARC level may be a potent marker reflecting better response to IL-17A inhibitors, and in this case step down of treatment for psoriasis is possible.

Published
2018

Catalog

Books, media, physical & digital resources
See catalog results